OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cardiology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
LIPC variant in combined hypocholesterolaemia	525
Antibody treatment to deplete transthyretin amyloid deposits in the heart	500
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	471
Intravascular imaging improves outcomes	444
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	440
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	398
The City Heartbeat Index as a benchmarking tool for urban cardiovascular health	356
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	351
Optimizing cardiovascular pharmacotherapy in older adults with frailty	329
Genetics and mechanisms of thoracic aortic disease	297
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	285
Takotsubo syndrome: pathophysiological insights and innovations in patient care	273
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	269
Alternative defibrillation strategies improve outcomes	265
Detection of subclinical hypertrophic cardiomyopathy	254
Defining iron deficiency in patients with heart failure	251
Drug-coated balloon angioplasty for coronary and peripheral artery disease: latest evidence and clinical indications	248
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	246
Base editing and silencing of PCSK9 shows clinical promise in humans	237
HFpEF and MASLD: converging mechanisms and clinical implications	229
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice	209
Think Aorta: aortic dissection awareness and perspectives from the patient	192
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	189
Hallmarks of cardiovascular ageing	185
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	175

Preparticipation screening reduces SCD in young athletes	174
Decongestion in heart failure: medical and device therapies	158
No benefit of apoA-I infusion after myocardial infarction	154
Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes	154
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	149
Catheter ablation improves outcomes in patients with AF and end-stage HF	146
Increased degradation of desmosomal proteins in ACM	145
LDL-cholesterol lowering with obicetrapib	140
Colchicine in acute coronary syndromes: the present and the possible future	138
CSDE1 regulates LDL receptor levels	132
Reactive oxygen species in hypertension	130
Extracellular matrix in vascular homeostasis and disease	128
Graded exercise therapy should not be recommended for patients with post-exertional malaise	128
Cardiac lymphatic dysfunction and repair in cardiovascular disease	124
Targeting immune cell recruitment in atherosclerosis	124
Tailored therapeutics for cardiomyopathies	123
The oral microbiome in the pathophysiology of cardiovascular disease	122
Donor macrophages influence rejection of transplanted hearts	121
Modelling pre-eclampsia and its cardiovascular effects	119
Cardiac sarcomere turnover by unidirectional replacement of proteins	118
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	115
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	114
Semaglutide is beneficial in patients with HFpEF and obesity	113
Calculation methods for LDL cholesterol are evolving tools for accuracy in lipidology	111
Evidence does not support the reduction of added sugar intake from all food sources	108
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	102
RNA interference lowers triglyceride levels	101
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	98
Local calcium dynamics and signalling in cardiomyocytes	97
Mitochondrial uncoupling therapy reduces established atherosclerosis in mice	92
Promising novel siRNA for the treatment of hypertension	90
An epigenome editing approach induces durable silencing of Pcsk9	84
Global epidemiology of heart failure	84
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	83
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	83
The role of the molecular autopsy in sudden cardiac death in young individuals	83
Tricuspid valve disease: updates on diagnostic imaging and intervention	82
Development of a miniature, bioresorbable, light-activated pacemaker	79
The gut metabolite imidazole propionate is a potential biomarker of and therapeutic target for atherosclerosis	77
Digital screening and decision-support tools in equitable preventive cardiology	76
Heart transplantation: advances in expanding the donor pool and xenotransplantation	73
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	72
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	71
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	70
Low alcohol intake might lower CVD risk by reducing stress-related brain activity	69
Efferocytosis in atherosclerosis	69
Baxdrostat beneficial in uncontrolled or resistant hypertension	66
PCSK9 inhibition for primary prevention of cardiovascular events	63
Gene–environment interactions in the pathogenesis of cardiovascular disease	62
Gut bacteria can break down cholesterol	62

New insights into dietary cholesterol absorption	61
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy	58
Cardiovascular benefits of fermented foods and beverages: still up for debate	57
Improving medication adherence in cardiovascular disease	55
Mechanisms and treatment of pulmonary arterial hypertension	53
Stenting for post-thrombotic syndrome	53
Renal denervation for hypertension	53
Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation	53
Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis	52
Cardiovascular disease and cancer: shared risk factors and mechanisms	50
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	50
Synthetic ion channel modulator reverses sodium channel dysfunction linked to cardiac arrhythmias	47
Cardiac optogenetics: controlling the heart with light	47
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	46
Epigenetic editing in cardiovascular medicine: moving beyond the hype	45
Integration of cardiovascular and mental health: from concepts to the clinic	44
Heart failure and obesity: novel insights leading to new treatment paradigms	44
The environmental exposome in heart failure risk and progression	43
Metabolites matter for gut microbiota as a modifiable risk factor in cardiovascular diseases	43
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	42
Transcriptional regulation in heart development, disease and regeneration: reassessing the fetal gene hypothesis	42
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	41
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	41
Black In Cardio: promoting diversity and representation in the cardiovascular field	41
Gout flares can precede cardiovascular events	40
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women	40
Sotatercept as add-on therapy for advanced PAH	38
Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition	37
Colchicine in patients with cardiovascular disease	37
Inhibiting aldosterone synthase reduces blood pressure	37
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	35
Age-induced senescence impairs the neurovascular interface in the heart	35
ASGR1 inhibition stimulates cholesterol excretion	35
Phase separation of protein kinase A: a new paradigm in cardiac regulation?	35
Consequences of ionizing radiation exposure to the cardiovascular system	35
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	33
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	33
Artificial intelligence-enhanced echocardiography in cardiovascular disease management	33
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	32
Surgery safer than endovascular therapy for CLTI	31
Characterization of the F8 gene: a silver lining in a dark cloud	31
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes	31
A distinct platelet differentiation pathway is involved in age-related thrombocytosis	30
Building the Australian Cardiovascular disease Data Commons	30
Preserving the future of heart transplantation	30
An ex vivo perfusion platform for the testing of cardiovascular interventional devices	29
Genome editing prevents hypertrophic cardiomyopathy in mice	29
Epidemiology of non-ischaemic dilated cardiomyopathy	28
A role for lipophagy in atherosclerosis	28
Leadless and extravascular cardiac resynchronization therapy: the future for CRT?	28
Vagal mechanoreceptors in the heart sense changes in blood volume	28
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies	27
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	26
Alain Cribier (1945–2024)	25
Implementing LGBTQ-inclusive policies for cardiology practice and the workforce	25
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	25
Unravelling the genetic heart–brain connection using MRI	22
Charting the future of cardiology with large language model artificial intelligence	22
Non-coding RNAs in lipid metabolism and their roles in atherosclerosis	21
Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity	21
Contemporary pharmacological treatment and management of heart failure	21
Cardiac splicing as a diagnostic and therapeutic target	21
Mind the gap: sex-related differences in cardiovascular disease	20
Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group	20
Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy	19
Wearable blood pressure sensors for cardiovascular monitoring and machine learning algorithms for blood pressure estimation	19
Current concepts and novel targets for antiplatelet therapy	18
Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease	18
Epidemiology and prevention of venous thromboembolism	18